5445582025-04-012025-06-305445582025-06-305445582025-04-012025-06-30in-capmkt:OtherExpenses1Member5445582025-04-012025-06-30in-capmkt:OtherExpenses2Member5445582025-04-012025-06-30in-capmkt:OtherExpenses3Member5445582025-04-012025-06-30in-capmkt:OtherExpenses4Member5445582025-04-012025-06-30in-capmkt:OtherExpenses5Member5445582025-04-012025-06-30in-capmkt:OtherExpenses6Member5445582025-04-012025-06-30in-capmkt:OtherExpenses7Member5445582025-04-012025-06-30in-capmkt:OtherExpenses8Member5445582025-04-012025-06-30in-capmkt:OtherExpenses9Member5445582025-04-012025-06-30in-capmkt:OtherExpenses10Member5445582025-04-012025-06-30in-capmkt:ReportableSegments1Member5445582025-04-012025-06-30in-capmkt:ReportableSegments2Member5445582025-04-012025-06-30in-capmkt:ReportableSegments3Member5445582025-04-012025-06-30in-capmkt:ReportableSegments4Member5445582025-04-012025-06-30in-capmkt:ReportableSegments5Member5445582025-04-012025-06-30in-capmkt:ReportableSegments6Member5445582025-04-012025-06-30in-capmkt:ReportableSegments7Member5445582025-04-012025-06-30in-capmkt:ReportableSegments8Member5445582025-04-012025-06-30in-capmkt:ReportableSegments1Member5445582025-04-012025-06-30in-capmkt:ReportableSegments2Member5445582025-04-012025-06-30in-capmkt:ReportableSegments3Member5445582025-04-012025-06-30in-capmkt:ReportableSegments4Member5445582025-04-012025-06-30in-capmkt:ReportableSegments5Member5445582025-04-012025-06-30in-capmkt:ReportableSegments6Member5445582025-04-012025-06-30in-capmkt:ReportableSegments7Member5445582025-04-012025-06-30in-capmkt:ReportableSegments8Member5445582025-04-012025-06-30in-capmkt:ReportableSegments1Member5445582025-06-30in-capmkt:ReportableSegments1Member5445582025-04-012025-06-30in-capmkt:ReportableSegments2Member5445582025-06-30in-capmkt:ReportableSegments2Member5445582025-04-012025-06-30in-capmkt:ReportableSegments3Member5445582025-06-30in-capmkt:ReportableSegments3Member5445582025-04-012025-06-30in-capmkt:ReportableSegments4Member5445582025-06-30in-capmkt:ReportableSegments4Member5445582025-04-012025-06-30in-capmkt:ReportableSegments5Member5445582025-06-30in-capmkt:ReportableSegments5Member5445582025-04-012025-06-30in-capmkt:ReportableSegments6Member5445582025-06-30in-capmkt:ReportableSegments6Member5445582025-04-012025-06-30in-capmkt:ReportableSegments7Member5445582025-06-30in-capmkt:ReportableSegments7Member5445582025-04-012025-06-30in-capmkt:ReportableSegments8Member5445582025-06-30in-capmkt:ReportableSegments8Member5445582025-04-012025-06-30in-capmkt:ReportableSegments1Member5445582025-06-30in-capmkt:ReportableSegments1Member5445582025-04-012025-06-30in-capmkt:ReportableSegments2Member5445582025-06-30in-capmkt:ReportableSegments2Member5445582025-04-012025-06-30in-capmkt:ReportableSegments3Member5445582025-06-30in-capmkt:ReportableSegments3Member5445582025-04-012025-06-30in-capmkt:ReportableSegments4Member5445582025-06-30in-capmkt:ReportableSegments4Member5445582025-04-012025-06-30in-capmkt:ReportableSegments5Member5445582025-06-30in-capmkt:ReportableSegments5Member5445582025-04-012025-06-30in-capmkt:ReportableSegments6Member5445582025-06-30in-capmkt:ReportableSegments6Member5445582025-04-012025-06-30in-capmkt:ReportableSegments7Member5445582025-06-30in-capmkt:ReportableSegments7Member5445582025-04-012025-06-30in-capmkt:ReportableSegments8Member5445582025-06-30in-capmkt:ReportableSegments8Member5445582025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares544558FABTECHNOTLISTEDINE0HF201011Fabtech Technologies LimitedMain BoardEquity2025-04-012026-03-312025-10-272025-10-23INRLakhsQuarterlyFirst quarterGeographical2025-10-2704:00:002025-10-2723:00:00Not applicable2025-04-012025-06-30UnauditedConsolidated68006800094510006895190000359102000714850001051790001341100013931000206435000769543000-8002400017749000-622750006468000-7156000-6880000-61587000000328000-61259000-337000-61596000-612590001000-61596000100032392200010-1.89-1.8900-1.89-1.891. The consolidated financial results of Fabtech Technologies Limited (the "Company") has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the"Act") and other accounting principles generally accepted in India and presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"). <BR> These results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2025. <BR> In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Limited review of the consolidated results of quarter ended June 30, 2025 has been carried out by the Statutory Auditors. <BR> 2. Previous Year's/Period's figures have been regrouped/rearranged/adjusted/rectified wherever considered necessary. <BR> 3. The figures for the year ended March 31, 2025 have been extracted from the consolidated financial statements which were audited by the Statutory Auditors of the Company. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2025 and the unaudited year to date figures up to period ended December 31, 2024, which were neither subject to review nor audit. However, the management has exercised necessary care to ensure that the consolidated financial results for that period are fairly stated. These figures are furnished by the mangement of the Company and were reviewed and recommended by the Audit committee and approved by the Board of Directors at their meeting held on October 27, 2025. <BR> 4. The figures for the corresponding quarter ended June 30, 2024 have not been subjected to a review or audit by the Statutory Auditors. However, the management has exercised necessary care to ensure that the consolidated financial results for that period are fairly stated. These figures are furnished by the mangement of the Company and were reviewed and recommended by the Audit committee and approved by the Board of Directors at their meeting held on October 27, 2025. <BR> 5. Subsequent to the quarter ended September 30, 2025, the Company has completed its initial public offer (IPO) of fresh issue of 1,20,60,000 equity shares of face value of Rs 10 each at an issue price of Rs 191. The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on October 7, 2025. The Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective from next reporting period based on actual utilisation of the funds pursuant to the IPO. Accordingly, these unaudited consolidated financial results for the quarter ended June 30, 2025 are drawn up for the first time in accordance with the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements). Regulations, 2015 as amended. <BR> 6. The reportable segments derives their revenues from turnkey projects solution provided to pharmaceuticals and allied industries by way of supplying pharmaceutical machineries / equipment,inhouse designing and engineering and to undertake other activities requiredinvarious pharmaceutical turnkeyprojects. The CODM reviews geographical revenue as the performance indicator. The measurement of geographical segment’s revenues and assets is consistent with the accounting policies that are used in preparation of the Group’s Consolidated Financial Results. The same is attached herewith as Annexure A to the Unaudited Consolidated Financial Results. <BR> 7. The exceptional item amounting to Rs. 177.49 Lakhs disclosed in the profit or loss statement for the quarter ended June 30, 2025, represents the profit arising from the sale of 51% stake in the subsidiary LLP. Prior to the transaction, the Company held 99.99% ownership interest in the Subsidiary LLP. Post Sale, the Company's ownership interest has reduced to 48.99%. This transaction is significant and non-recurring in nature and has been presented separately as an exceptional item to provide clarity and transparency to the users of the financial results. <BR> 8. The exceptional item amounting to Rs. 1,784.86 Lakhs disclosed in the Statement of Profit and Loss for the quarter ended June 30, 2024, represents the profit arising from the sale of a 51% equity stake in the associate. Prior to this transaction, the Company held a 33.33% ownership interest in the associate. Post-sale, the Company’s ownership has reduced to 16.33%, which has been classified as “Asset Held for Sale” as disclosed in the audited financial statements for the year ended March 31, 2025. This transaction is significant and non-recurring in nature and has therefore been presented separately as an exceptional item to ensure greater clarity and transparency for users of the financial statements. <BR> 9. The unaudited consolidated financial results are also being made available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website: www.fabtechnologies.com. <BR> Business Promotion and Advertising17878000Project erection and commissioning expenses46676000Travelling and Conveyance expenses32879000Freight and forwarding75337000Legal and professional charges8611000Provision for Doubtful Debt and advances2921000Insurance1782000Communication expenses2346000Corporate Social Responsibility Expenses1473000Other Expenses16532000UAE402421000Saudi Arabia74395000Egypt44342000India107023000Sri Lanka4685000Algeria9806000Kenya0Rest of the world11017100075284300072785000680058000UAE0Saudi Arabia0Egypt0India0Sri Lanka0Algeria0Kenya0Rest of the world000UAE364164000Saudi Arabia317612000Egypt36784000India350119000Sri Lanka25700000Algeria29849000Kenya2992000Rest of the world345269000147248900001472489000UAE0Saudi Arabia0Egypt0India0Sri Lanka0Algeria0Kenya0Rest of the world0000Segment Trade Receivable for the period is disclosed under Segment AssetsRemeasurement gain/ (loss) of defined benefit plans-450000-450000-113000-337000